On a roll, Sage grabs a $575M deal on lim­it­ed Asian rights to SAGE-217 — a po­ten­tial gamechang­er in de­pres­sion

The da­ta may be ear­ly and the pa­tient pop­u­la­tion small, but in biotech to­day, who’s wait­ing for com­plete clar­i­ty? 

On the day af­ter the FDA blessed Sage Ther­a­peu­tics $SAGE with its in­side track on their oral de­pres­sion drug SAGE-217, Japan’s Sh­iono­gi has stepped in with a $575 mil­lion deal to gath­er up lim­it­ed Asian rights to the drug — with $90 mil­lion com­ing in as cash up­front.

Sage is on a roll, and they know it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER